Lacticaseibacillus rhamnosus GG (LGG)
Also called: Lactobacillus rhamnosus GG, LGG, L. rhamnosus GG, L. rhamnosus ATCC 53103
Lacticaseibacillus rhamnosus GG (LGG), formerly Lactobacillus rhamnosus GG, is a probiotic bacterial strain with the reference strain ATCC 53103. Its genus name changed when Lactobacillus was split into 25 genera in 2020. Probiotic effects are strain specific; results here are for LGG.
- Category
- Probiotic
- Forms
- Live bacteria (L. rhamnosus GG); amounts stated in colony-forming units (CFU)
- Strongest evidence
- B Some positive trials
- Reviewed
- 2026-10-30
Class 1 Well studied in people. A 2015 meta-analysis included 12 RCTs (1,499 children and adults) of L. rhamnosus GG versus placebo or no treatment for antibiotic-associated diarrhea. [4]
Fact-checked 2026-10-30 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
BLungs and airways1 topic
XSkin and hair1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Antibiotic-associated diarrhea | B | A 2015 meta-analysis of 12 RCTs (1,499 participants) found LGG lowered risk from 22.4% to 12.3% (11 RCTs; low-quality evidence); the reduction was significant in children (5 RCTs) but not in adults overall (6 RCTs). [4] |
| Duration of diarrhea in children with acute gastroenteritis (pooled trials) | B | A 2019 meta-analysis of 18 RCTs (4,208 children) found LGG shortened diarrhea by 0.85 day and hospital stays, with no effect on stool volume; heterogeneity was high and trials had methodological limitations. [5] |
| Acute gastroenteritis in US preschool children (large RCT) | X | In a double-blind trial of 971 children aged 3 months to 4 years in 10 US emergency departments, a 5-day LGG course (1 x 10^10 CFU twice daily) did not improve outcomes versus placebo. [6] |
| Abdominal pain-related functional GI disorders in children | B | A 2011 meta-analysis (3 RCTs, 290 children) found more treatment responders with LGG than placebo (RR 1.31), especially in irritable bowel syndrome; no difference in functional abdominal pain or dyspepsia. [7] |
| Eczema risk in young children | X | A meta-analysis of five RCTs (889 participants) found LGG, given to children or to mothers in pregnancy or breastfeeding, did not reduce eczema risk up to age 4. [1] |
| Respiratory infections | B | A 2025 meta-analysis of 69 LGG trials found lower respiratory infection risk (RR 0.87; 18 trials) but limited effects on respiratory symptoms; certainty was mostly low beyond diarrhea outcomes and adult evidence was limited. [8] |
Main constituents: Lacticaseibacillus rhamnosus GG, formerly Lactobacillus rhamnosus GG (nickname LGG) [1]; Genus Lacticaseibacillus: one of 23 novel genera proposed in the 2020 reclassification of Lactobacillus [2]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- Antibiotic-associated diarrhea trials: 4 x 10^8 to 12 x 10^10 CFU LGG for 10 days to 3 months; 1 to 2 x 10^10 CFU/day reduced the risk in children by 71%. [1]
- Pediatric infectious diarrhea: an 11-RCT assessment (2,444 participants) found LGG most effective at a daily dose of at least 10^10 CFU. [1]
- Preterm infants: ESPGHAN continues to recommend LGG (1 to 6 x 10^9 CFU) to reduce necrotizing enterocolitis risk, a weak recommendation with low certainty of evidence. [1]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)Nothing found
No published information found in the sources checked.
Details and sources - Pregnancy and breastfeedingIn a meta-analysis of five RCTs (889 participants), LGG given via maternal supplementation in utero and/or during breastfeeding, or directly to …
1 statement in the profile.
Details and sources - Interactions with medicines1 listed
Antibiotics (timing)
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notificationsNone on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsStated
Health Canada probiotics monograph (April 24, 2026), Lacticaseibacillus rhamnosus GG: management of acute infectious diarrhea 6.0 x 10^9 to 1.2 x …
Details and sources
- In a Boston ICU study of 22,174 patients, genome-level analysis identified LGG in the blood of 6 of 522 patients who received LGG versus 2 of 21,652 who did not; recipients were typically fed by feeding tube. [1]
- After LGG was introduced into dairy products in Finland in 1990, monitoring through 2000 showed no increase in Lactobacillus bacteremia. [1]
- FDA (2023, probiotics in general): administering probiotics to preterm infants may cause infection or invasive and potentially fatal disease; FDA reported one infant death and more than two dozen other adverse events. [1]
- Health Canada's probiotics monograph: do not use if you have an immune-compromised condition (for example AIDS, lymphoma or long-term corticosteroid treatment). [9]
Interactions
| With | What happens |
|---|---|
| Antibiotics (timing) | Health Canada's probiotics monograph directs taking bacterial probiotics, including L. rhamnosus GG, at least 2–3 hours before or after antibiotics. [9] |
Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.
Identity, quality and standardization
- Two of three dairy isolates of LGG had lost genome segments including the spaCBA pilus genes, and two more commercial products contained mixed LGG variants with or without spaC. [3]
- US labels must list total microorganism weight, which can include live and dead cells; CFU may be listed voluntarily. [1]
Regulatory status
- Canada: listed in Health Canada's probiotics monograph (April 24, 2026) with uses for acute infectious diarrhea and antibiotic-associated diarrhea. [9]
- US: No NDI notification naming Lacticaseibacillus (Lactobacillus) rhamnosus GG was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-29); other L. rhamnosus strains appear. FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [10]
- US: FDA states that under DSHEA it does not have the authority to approve dietary supplements before they are marketed; a firm is responsible for ensuring its products are not adulterated. [11]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
- Live Lacticaseibacillus rhamnosus GG (formerly Lactobacillus rhamnosus GG) Probiotic bacterium (family Lactobacillaceae) [P1]
US status
What FDA's published records show. FDA does not approve dietary supplements.
- No NDI notification naming Lacticaseibacillus (Lactobacillus) rhamnosus GG was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-29); other L. rhamnosus strains appear. FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [P2]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
- No IARC or NTP carcinogenicity evaluation of Lacticaseibacillus rhamnosus GG was found (IARC Monographs list of classifications and NTP technical reports checked 2026-10-29). [P3]
Liver (NIH LiverTox)
- No published information found in the sources checked.
Interactions with medicines
- Antibiotics (timing): Health Canada's probiotics monograph directs taking bacterial probiotics, including L. rhamnosus GG, at least 2–3 hours before or after antibiotics. [P4]
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- Sybesma et al. (2013) compared three dairy isolates of LGG with the ATCC 53103 reference strain: two had lost 34 or 84 genes from genomic islands, including spaCBA; qPCR showed two more commercial probiotic products contained heterogeneous LGG populations. [P5]
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity: at least one appropriate test or examination to verify the identity of each component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)) — General Part 111 requirement for every dietary ingredient; FDA may exempt a firm only by granting a petition under 111.75(a)(1)(ii). [P6]
- Strain identity by phenotype and genotype (genome-based comparison to type strains and whole-genome strain characterization) — Required by Health Canada's probiotics monograph. [P4]
- Genotype stability check (for example qPCR for spaC) — LGG variants lacking spaC were found in dairy isolates and commercial products; the authors call for quality controls on genome stability. [P5]
- Viable count (CFU) at end of shelf life — Health Canada requires at least 80% of the label-declared quantity at the end of shelf life. [P4]
Supply and conservation
- No published information found in the sources checked.
Absorption in people
- No published information found in the sources checked.
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- Health Canada probiotics monograph (April 24, 2026), Lacticaseibacillus rhamnosus GG: management of acute infectious diarrhea 6.0 x 10^9 to 1.2 x 10^10 CFU/day; management/risk reduction of antibiotic-associated diarrhea 1.0 x 10^10 to 2.0 x 10^10 CFU/day. [P4]
Pregnancy and breastfeeding
- In a meta-analysis of five RCTs (889 participants), LGG given via maternal supplementation in utero and/or during breastfeeding, or directly to children, did not reduce eczema risk up to age 4. [P1]
Sources for this profile
- NIH Office of Dietary Supplements. Probiotics: Fact Sheet for Health Professionals (Updated March 25, 2025), 2025-03-25. ods.od.nih.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs. List of Classifications: agents classified by the IARC Monographs, Volumes 1–142 (last updated 2026-07-23), 2026-07-23. monographs.iarc.who.int
- Health Canada, NNHPD. Natural health product monograph: Probiotics (date April 24, 2026), 2026-04-24. webprod.hc-sc.gc.ca
- Sybesma W, et al. Genome instability in Lactobacillus rhamnosus GG. Appl Environ Microbiol 2013;79(7):2233-9 (PMID 23354703), 2013-04. pubmed.ncbi.nlm.nih.gov
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
Sources
- NIH Office of Dietary Supplements. Probiotics: Fact Sheet for Health Professionals (Updated March 25, 2025), 2025-03-25. ods.od.nih.gov
- Zheng J, et al. A taxonomic note on the genus Lactobacillus: description of 23 novel genera, emended description of the genus Lactobacillus Beijerinck 1901, and union of Lactobacillaceae and Leuconostocaceae. Int J Syst Evol Microbiol 2020;70(4):2782-2858 (PMID 32293557), 2020-04. pubmed.ncbi.nlm.nih.gov
- Sybesma W, et al. Genome instability in Lactobacillus rhamnosus GG. Appl Environ Microbiol 2013;79(7):2233-9 (PMID 23354703), 2013-04. pubmed.ncbi.nlm.nih.gov
- Szajewska H, Kołodziej M. Systematic review with meta-analysis: Lactobacillus rhamnosus GG in the prevention of antibiotic-associated diarrhoea in children and adults. Aliment Pharmacol Ther 2015;42(10):1149-57 (PMID 26365389), 2015-11. pubmed.ncbi.nlm.nih.gov
- Szajewska H, et al. Systematic review with meta-analysis: Lactobacillus rhamnosus GG for treating acute gastroenteritis in children - a 2019 update. Aliment Pharmacol Ther 2019;49(11):1376-1384 (PMID 31025399), 2019-06. pubmed.ncbi.nlm.nih.gov
- Schnadower D, et al. Lactobacillus rhamnosus GG versus placebo for acute gastroenteritis in children. N Engl J Med 2018;379(21):2002-2014 (PMID 30462938), 2018-11-22. pubmed.ncbi.nlm.nih.gov
- Horvath A, et al. Meta-analysis: Lactobacillus rhamnosus GG for abdominal pain-related functional gastrointestinal disorders in childhood. Aliment Pharmacol Ther 2011;33(12):1302-10 (PMID 21507030), 2011-06. pubmed.ncbi.nlm.nih.gov
- Hidayat K, et al. The effects of Lacticaseibacillus rhamnosus GG supplementation on gastrointestinal and respiratory outcomes: a systematic review and meta-analysis of randomized controlled trials. Food Funct 2025;16(16):6275-6292 (PMID 40702885), 2025-08-11. pubmed.ncbi.nlm.nih.gov
- Health Canada, NNHPD. Natural health product monograph: Probiotics (date April 24, 2026), 2026-04-24. webprod.hc-sc.gc.ca
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in probiotic: Akkermansia muciniphila (pasteurized) · Bacillus coagulans (Heyndrickxia coagulans) · Bifidobacterium animalis subsp. lactis BB-12 · Escherichia coli Nissle 1917 (EcN) · Lacticaseibacillus paracasei strain Shirota (LcS) · Lactiplantibacillus plantarum 299v · Limosilactobacillus reuteri DSM 17938 · Probiotics · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.